维昇药业-B（股票代码：02561）于2026年6月29日公布翌日披露报表，披露6月29日于香港联合交易所场内回购股份的具体信息。
本次回购股份数量为4,300股，占回购前已发行股本（不包括库藏股）约0.004%。回购价格每股介乎港币19.18元至港币20元，涉及总金额84,641港元，折合约8.46万港元。
回购完成后，公司已发行股本（不包括库藏股）为113,753,364股，库藏股数量增加至173,500股，总发行股本维持在113,926,864股。公司回购授权由股东于2026年6月26日批准，授权可回购股份数量为11,375,766股。截至目前，公司已在香港联交所购回4,300股，占回购授权通过当日已发行股本的约0.00378%。公司还披露，该次回购完成后，适用的三十天暂止期将持续至2026年7月29日。
根据公告，公司确认已遵守香港联交所证券上市规则及相关法律法规。本次公告由执行董事卢安邦签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.